Home > Oncology > Is bone health being overlooked in men on ADT for prostate cancer?

Is bone health being overlooked in men on ADT for prostate cancer?


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Network Open
Reuters Health - 08/04/2022 - A new study suggests a gap in bone-health management and fracture prevention in men with prostate cancer receiving androgen-deprivation therapy (ADT). Rates of dual-energy x-ray absorptiometry (DXA) screening to assess bone-mineral density (BMD) have increased since the early 2000s, but remain low, the study found. Prostate cancer accounts for 26% of all new cancers in men and ADT is the mainstay of treatment, which can adversely affect bone health. "Given the deleterious impact of fractures for morbidity and mortality, implementation strategies are needed to increase the uptake of current guidelines for bone health management among men with prostate cancer," write Dr. Maria E. Suarez-Almazor of the University of Texas MD Anderson Cancer Center in Houston and colleagues in JAMA Network Open. "Early intervention with bone-modifying agents could potentially reduce the burden of illness associated with fractures among older m...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on